Head-to-Head: Expedite Clinical Trials
INC Research’s Dr. John Potthoff and MDS Pharma Services’ David Spaight discuss how e-solutions and web-based applications impact clinical trials processes.
More >>

Portfolio management
Richard Sonnenblick, President of Enrich, John Howell, Founder and President of Portfolio Decisions and Dr. James Mattheson, Chariman and CFO of SmartOrg Inc. talk about maximizing profitability, achieving a balance and the ever-changing landscape of portfolio management.
More >>

Head to head: The future of cell biology
Kevin Daugherty, Director of Marketing for Greiner Bio-One, and Dr. David Kirk, Technical Director of MDS Pharma Services, sit down to discuss molecular and cell biology, improved tissue devices and the biggest potential for cell culture.
More >>

Head to head: with big pharma
Amgen, a small West Coast based biotech who was hardly on the map ten years ago, last year produced four of the top 20 drugs in the US market by sales.
More >>

Head to head: The future of web-based reporting
Dr. Steven Gold, Founder and CEO of GraphLogic, and Dr. Simon Wood, Executive Director of Marketing and Education for STARLIMS, discuss superior alternatives to traditional software.
More >>

The Marketing Head-to-Head
NGP asked Yaron Inbar, President and Chief Operating Officer at Publicis e-Health and Kevin Sanborn, Executive Vice President at Thomson Healthcare about market research teams, key opinion leaders and future marketing strategies.
More >>

Executive Insight: Clinical Trials
Vito Mangiardi, President of North American Operations at AAIPharma, and David Spaight, President of MDS Pharma, talk clinical trials, ethical standards, CROs and where the industry is heading.
More >>

HEAD-TO-HEAD
Grid technology is here to stay
More >>

Market Research
More >>

Head to head
Unraveling the DNA sequence
More >>

Driving discovery
Drug discovery needs all the help it can get. NGP talks problems and solutions with four gene genies: IQuum’s Shuqi Chen, Sequenom’s Elizabeth Dragon, Cellumen’s D. Lansing Taylor, and Rollie Carlson from Asuragen.
More >>

Marketing success
In order to garner a greater understanding of the marketing landscape in pharma.
More >>

“Bio and life sciences researchers are not computer scientists”
“Bio and life sciences researchers are not computer scientists” Penguin Computing’s Pauline Nist and Cluster Resources’ David Jackson talk technology and pharma, capabilities and potential.
More >>

Executive forum: Vital statistics
Informatics has the potential to drive growth in the worldwide pharmaceuticals drug market to a massive US$3 trillion by 2020, according to research
More >>

Executive forum
Push or pull: is pharma missing the selling point?
More >>

Grid technology: From hype to hope
Can pharma justify more widespread grid adoption?
More >>

Executive roundtable: targeting top talent
Kelly Scientific Resources’ Chris Jock, Kelly Engineering Resources’ Teresa Carroll, Randstad’s Joe Guariano and Vinay Nayak of Aerotek on the hunt for talent.
More >>

Executive roundtable: cutting costs with contract manufacturing
With Laureate Pharma’s Robert J. Broeze, EaglePicher Pharmaceutical Services’ Scott Parker and Dr Graeme Macaloney of QSV Biologics.
More >>

Executive roundtable: pharma marketers make their mark
EMM Group’s Gordon Wade, TNS Healthcare’s Elaine Riddell and Joseph E. Kuchta of Goble & Associates on how to build brand cache and consumer loyalty. Scott Parker and Dr Graeme Macaloney of QSV Biologics.
More >>

Umetrics - Manufacturing Roundtable: Lay it on the line
The PAT initiative aims, among other things, to develop processes that ensure consistent quality of the end product, while improving efficiency and addressing regulatory concerns.
More >>

Amaxa - Drug Discovery & Development Roundtable: Analyze this!
Five industry experts, all sharing one ultimate goal, discuss the real differences that a new generation of unique tools can and are making in drug discovery and development today.
More >>

TERANODE - LIMS Roundtable: Reign it, tame it and make it work for you
A core focus of this edition of NGP is how best to take control of the mass of data generated and processed in the pharma industry, something that currently presents a significant challenge and creates costly inefficiencies.
More >>

Cognos - Business Stratrgy Roundtable: How are your vital signs?
By knowing the lay of the land both within the organization ? where your inefficiencies and indeed your strengths lie ? and within the marketplace, you are in the best position to act.
More >>